December special issue of SLAS Discovery features 'drug discovery targeting COVID-19'

November 17, 2020

Oak Brook, IL - The December edition of SLAS Discovery, "Drug Discovery Targeting COVID-19" is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.

In this Special Issue, you will find seven papers published as open access articles. The issue includes four reviews that cover the commonly utilized approach of repurposing drugs to rapidly treat COVID-19, as well as targeting the virus using new vaccines and clinical drugs.

The articles of original research focus on novel proteins necessary for virus replication. The article, "High-Throughput Screening for Drugs that Inhibit Papain-Like Protease in SARS-CoV-2," explores how an ultra-high throughput screening platform targeting PLPro was used to investigate over 13,000 clinically applicable drugs. The article, "Discovery of Drug-Like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3" tests drug-like ligands for their efficacy against the MAC domain of SARS2 Nsp3, a novel approach. In addition to these two articles, the December special issue contains an additional two articles of original research.

Articles of Original Research include: Other articles include:
-end-
Access to December's SLAS Discovery issue is available at https://journals.sagepub.com/toc/jbxb/25/10. For more information about SLAS and its journals, visit http://www.slas.org/journals. Access a "behind the scenes" look at the latest issue with SLAS Discovery Author Insights podcast. Tune in by visiting https://www.buzzsprout.com/1099559.

SLAS (Society for Laboratory Automation and Screening) is an international professional society of academic, industry and government life sciences researchers and the developers and providers of laboratory automation technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS Discovery: Advancing the Science of Drug Discovery, 2019 Impact Factor 2.195. Editor-in-Chief Robert M. Campbell, Ph.D., Twentyeight-Seven Therapeutics, Boston, MA (USA).

SLAS Technology: Translating Life Sciences Innovation, 2019 Impact Factor 2.174. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore).

SLAS (Society for Laboratory Automation and Screening)

Related Genome Sequencing Articles from Brightsurf:

Tracking the SARS-CoV-2 virus with genome sequencing
Dirk Dittmer, PhD, professor of microbiology and immunology at the UNC School of Medicine, is tracking the virus that causes COVID-19 by sequencing the genome of virus samples collected from diagnostic testing.

Genome sequencing accelerates cancer detection
Recent cancer studies have shown that genomic mutations leading to cancer can occur years, or even decades, before a patient is diagnosed.

Whole genome sequencing reveals genetic structural secrets of schizophrenia
UNC School of Medicine scientists have conducted the largest-ever whole genome sequencing study of schizophrenia to provide a more complete picture of the role the human genome plays in this disease.

Using whole-genome sequencing for early identification and containment of AMR pathogens
A study published today examines the evolutionary and epidemiologic history of an epidemic strain of extensively drug-resistant tuberculosis (XDR-TB) -- called LAM4/KZN.

Whole genome sequencing could help save pumas from inbreeding
The first complete genetic sequences of individual mountain lions point the way to better conservation strategies for saving threatened populations of the wild animals.

Researchers move beyond sequencing and create a 3D genome
St. Jude Children's Research Hospital scientists have taken whole genome sequencing to the next level by creating a 3D map of the genome to better understand development and disease.

Clinical utility of rapid whole genome sequencing in neonates with seizures
Clinical utility of rWGS in the evaluation of neonatal seizures.

Viral genome sequencing in the heart of a Lassa outbreak
The first researchers to deploy a mobile nanopore sequencing technology to evaluate viral genomics at the height of a Lassa virus outbreak in 2018 now report their results.

New era for blood transfusions through genome sequencing
In a new study, investigators from Brigham and Women's Hospital and Harvard Medical School, as well as from the New York Blood Center have leveraged the MedSeq Project -- the first randomized trial of whole genome sequencing in healthy adults -- to develop and validate a computer program that can comprehensively and cost-effectively determine differences in individuals' blood types with more than 99 percent accuracy.

Does genome sequencing increase downstream costs?
The MedSeq Project, led by investigators at Brigham Women's Hospital, is the first randomized trial to provide whole genome sequencing to both presumably healthy patients as well as those with a known cardiology issue.

Read More: Genome Sequencing News and Genome Sequencing Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.